TRAVATAN (travoprost), glaucoma eye drops
OPHTHALMOLOGY - New indication
Opinions on drugs - Posted on Feb 03 2017
Reason for request
Extension of indication
No clinical benefit demonstrated in paediatric patients, by comparison with its comparators, in the reduction of elevated intraocular pressure
- TRAVATAN now has Marketing Authorisation in the reduction of elevated intraocular pressure (IOP), from 2 months of age, in paediatric patients with intraocular hypertension or glaucoma.
- A study has demonstrated its non-inferiority relative to timolol after 12 weeks of treatment on the reduction of IOP in children.
- No long-term safety data are available.
- TRAVATAN contains excipients that may cause a skin reaction.
Improvement in actual benefit
Évaluation des médicaments